ProShare Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $603K | Sell |
34,834
-2,862
| -8% | -$39.2K | ﹤0.01% | 984 |
|
|
2026
Q1 | $469K | Sell |
37,696
-3,685
| -9% | -$49.5K | ﹤0.01% | 1102 |
|
|
2025
Q4 | $521K | Buy |
41,381
+4,461
| +12% | +$51K | ﹤0.01% | 1114 |
|
|
2025
Q3 | $370K | Sell |
36,920
-5,641
| -13% | -$50.6K | ﹤0.01% | 1287 |
|
|
2025
Q2 | $344K | Sell |
42,561
-5,869
| -12% | -$44.2K | ﹤0.01% | 1350 |
|
|
2025
Q1 | $406K | Sell |
48,430
-11,063
| -19% | -$92.3K | ﹤0.01% | 1211 |
|
|
2024
Q4 | $471K | Buy |
59,493
+29,424
| +98% | +$247K | ﹤0.01% | 1307 |
|
|
2024
Q3 | $250K | Buy |
30,069
+13,742
| +84% | +$107K | ﹤0.01% | 1585 |
|
|
2024
Q2 | $104K | Sell |
16,327
-5,575
| -25% | -$35.4K | ﹤0.01% | 1659 |
|
|
2024
Q1 | $133K | Buy |
21,902
+1,726
| +9% | +$9.73K | ﹤0.01% | 1769 |
|
|
2023
Q4 | $122K | Buy |
20,176
+4,341
| +27% | +$19.3K | ﹤0.01% | 1751 |
|
|
2023
Q3 | $66.8K | Sell |
15,835
-19
| -0.1% | -$71 | ﹤0.01% | 1688 |
|
|
2023
Q2 | $49.1K | Buy |
15,854
+3,733
| +31% | +$7.95K | ﹤0.01% | 1773 |
|
|
2023
Q1 | $16.8K | Sell |
12,121
-1,132
| -9% | -$2.25K | ﹤0.01% | 1744 |
|
|
2022
Q4 | $26.4K | Buy |
13,253
+1,900
| +17% | +$4.26K | ﹤0.01% | 1793 |
|
|
2022
Q3 | $23K | Sell |
11,353
-216
| -2% | -$605 | ﹤0.01% | 1711 |
|
|
2022
Q2 | $37K | Sell |
11,569
-7,137
| -38% | -$25.9K | ﹤0.01% | 1734 |
|
|
2022
Q1 | $78K | Sell |
18,706
-3,076
| -14% | -$13.6K | ﹤0.01% | 2071 |
|
|
2021
Q4 | $105K | Buy |
21,782
+9,006
| +70% | +$44.9K | ﹤0.01% | 2194 |
|
|
2021
Q3 | $68K | Sell |
12,776
-13,094
| -51% | -$65.9K | ﹤0.01% | 1949 |
|
|
2021
Q2 | $132K | Sell |
25,870
-654
| -2% | -$3.72K | ﹤0.01% | 2242 |
|
|
2021
Q1 | $179K | Buy |
26,524
+4,552
| +21% | +$25.2K | ﹤0.01% | 2068 |
|
|
2020
Q4 | $100K | Buy |
21,972
+9,816
| +81% | +$43.5K | ﹤0.01% | 1988 |
|
|
2020
Q3 | $47K | Sell |
12,156
-1,324
| -10% | -$5.66K | ﹤0.01% | 1598 |
|
|
2020
Q2 | $64K | Buy |
+13,480
| New | +$55.5K | ﹤0.01% | 1617 |
|
|
2020
Q1 | – | Sell |
-16,027
| Closed | -$77K | – | 1183 |
|
|
2019
Q4 | $77K | Buy |
16,027
+5,353
| +50% | +$18.6K | ﹤0.01% | 1717 |
|
|
2019
Q3 | $31K | Sell |
10,674
-480
| -4% | -$1.68K | ﹤0.01% | 1629 |
|
|
2019
Q2 | $80K | Sell |
11,154
-1,484
| -12% | -$15.2K | ﹤0.01% | 1552 |
|
|
2019
Q1 | $179K | Buy |
12,638
+1,161
| +10% | +$15.3K | ﹤0.01% | 1499 |
|
|
2018
Q4 | $155K | Sell |
11,477
-1,790
| -13% | -$32.3K | ﹤0.01% | 1420 |
|
|
2018
Q3 | $294K | Buy |
13,267
+39
| +0.3% | +$821 | ﹤0.01% | 1369 |
|
|
2018
Q2 | $217K | Buy |
+13,228
| New | +$232K | ﹤0.01% | 1569 |
|
Other funds holding AMRX
TGA
RCMNY
ProShare Advisors's AMRX Position: Q2 2026 in Review
ProShare Advisors reduced its Amneal Pharmaceuticals (AMRX) stake by 7.6% in Q2 2026, selling an estimated $39.2K and leaving 34,834 shares worth $603K. The position accounts for ﹤0.01% of the portfolio, ranked #984.
ProShare Advisors first reported a position in AMRX in Q2 2018 and has held it in 32 quarters since. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.
- ProShare Advisors held 34,834 shares of Amneal Pharmaceuticals worth $603K as of Q2 2026.
- ProShare Advisors sold 2,862 Amneal Pharmaceuticals shares in Q2 2026, an estimated $39.2K.
- Amneal Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #984 holding.
- ProShare Advisors first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 32 quarters since.
- 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.
Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.